Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross Muken.
A new report says the Japanese CRO market is seeing more growth as Japanese pharma firms, which traditionally kept research in-house, are now broadening their horizons to use more outsourcing partners.
As the European Medicines Agency (EMA) announces final consultations on its clinical trial data policy will begin at the start of May, we take a look at the issues surrounding trial transparency in Europe.
Pharmaceutical clients view contract research organisations (CROs) with private equity investments as unstable and more focused on financial growth than their operations, according to Italian CRO Cromsource.
As larger partnerships between CROs and sponsors come to maturity, a new survey found that “a much greater proportion of CRO revenue growth” will come from small and medium-sized pharma and biotech sponsor deals.
Industry group TransCelerate Biopharma has certified that training programs from CROs Icon and SynteractHCR meet minimum criteria for ICH’s good clinical practice (GCP) training.
A recent study found that CRO employees are seeing rapid budget increases for salaries across the globe, with an average increase of about 4% for 2014.
Karyopharm Therapeutics has selected CRO Clinipace to help discover first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases,
Patient recruitment is “the major bottleneck” in clinical development, an Industry Standard Research report says, but though it predicts a drive to ‘push’ patients into trials, industry disagrees.
Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst firm Jeffries.
The National Institute for Health Research (NIHR) Clinical Research Network, which provides more than £284m ($475m) a year to support the delivery of clinical research studies, has reconfigured to become 15 local clinical research networks across England.
Genentech says its collaboration with PatientsLikeMe will enable more effective clinical trial recruitment but will not affect its partnerships with CROs.
Almost two-thirds of supply chain executives plan to increase their expenditure in clinical trial logistics over the next two years, according to an industry survey conducted by Marken.
As smaller biotech, pharma and medical device companies seem keen to expand R&D, they also seem to be consistently turning to mid-size CROs to run their trials.
Big Pharma's split opinion on the best way to work with a CRO was in evidence in Las Vegas this week with Pfizer underlining its commitment to strategic deals and Merck KGaA backing a multi-vendor model.
Pharmaceutical companies will be made to publish all European clinical trials in a public database under a draft law passed by the European Parliament yesterday.
CRO BioClinica has signed two multi-year contract extensions worth $30m for cloud-based technologies and professional services and training across its e-clinical product suite.
Ireland-based CRO Icon has agreed, subject to certain closing conditions, to acquire Aptiv Solutions for $143.5m in cash to further expand its adaptive trial offerings.
As biopharma companies look to develop cancer therapies more quickly, some are turning to CROs with the hopes of using surrogate endpoints to expedite US FDA approval.
Parexel has enlarged its clinical trial supply network with the opening of a distribution centre in Singapore and expansion of its Massachusetts facilities.
Cloud-based community provider Exostar has selected Parexel as the latest CRO to become a member of its life science community, which aims to reduce the cost and burdens of collaborations between companies.
Nearly 40% of the $51bn spent on clinical development last year was outsourced according to Quintiles, which has predicted continued growth for the CRO industry in documents outlining its second public offering.
In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.
Susan Thornton PhD, president and CEO of Celerion, broke down the company’s recent moves to partner with Seoul National University Hospital in an Outsourcing-Pharma.com exclusive.
Scientists developing vaccines for potentially deadly diseases like influenza, SARS and HIV struggle to find a CRO with the right capabilities according to contractor TNO Triskelion.
Despite investor concerns about growth in R&D dollars for big pharma, CROs (contract research organizations) will benefit from the continued outsourcing, according to Citi analysts.
With a growing demand for comparative effectiveness data and questions on quality research persisting, Quintiles teamed with the National Pharmaceutical Council to develop and test a checklist to evaluate the quality and usefulness of observational research...
A history of recreational drug use normally stops someone taking part in a trial, but growing US FDA pressure for data on a drug’s abuse potential has prompted CROs to start recruiting users says INC Research.
CRO Pharmaceutical Product Development (PPD) and the Charité – Universitätsmedizin hospital in Berlin are collaborating to increase the volume of clinical trials conducted in Germany.
CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.
Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.
WCCT Global has launched a patient recruitment platform it says speeds up recruitment time and can cut sponsor costs with a more targeted advertising campaign.
DaVita Clinical Research has formed a pact with Pyxant Labs where Pyxant will provide bioanalytical laboratory services for DCR's early-phase clinical trials.
In an exclusive Q&A, new ACRO Chairman Ciaran Murray says conducting trials in countries such as China and India is critically important for speeding up drug development.
In an exclusive interview, Parexel’s president told Outsourcing-Pharma.com small pharma is increasing demand for CROs, commercialisation services are growing, and strategic partnerships are changing.
Covance has sold its high-complexity genomics laboratory to LabCorp as part of what an analyst says is decisive action to shed underperforming assets in its Early Development business.
Demand for early phase services have increased but the industry is still “far away from the boom times of the early to mid 2000s,” according to an ISI analyst.
